AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (82)

Latest Posts

About This Stock More About This Stock
S Hopes For A Peace Accord
Article By: Vivian Lewis
Monday, March 14, 2022 3:02 PM EDT
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.
In this article: ABB, AZN, BCE, EC, MRK, PBR, PFE, SLB, SAN, VALE, ESALY, RHHBY, TCEHY, NVAX, BIIB, TEVA, MRNA, CTRA, UUUU, BNTX
Read
70 Firms Going Ex-Dividend Next Week, Including GlaxoSmithKline, Dow And AstraZeneca
Article By: Timothy J. McIntosh
Saturday, February 19, 2022 7:24 PM EDT
Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend. 
In this article: AZN, DEO, DOW, EXC, GSK, MGA, UL, RTX
Read
AstraZeneca Records Bumper COVID-19 Vaccine Sales Of $4B In FY21
Article By: Benzinga
Thursday, February 10, 2022 7:19 AM EDT
Core earnings per share (EPS) came in at $1.67, topping estimates of $0.73.
In this article: AZN
Read
AstraZeneca: Expected To Move Upwards
Article By: AAATrade
Friday, November 12, 2021 9:43 AM EDT
Today’s instrument is the Astrazeneca Plc. stock traded in the LSE exchange under the ticker AZN.
In this article: AZN
Read
4 No-Brainer Pharmaceutical Stocks To Buy In October
Article By: StockNews
Monday, September 27, 2021 9:00 PM EDT
While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical industry.
In this article: ALPMY, AZN, GSK, JNJ
Read

Latest Tweets for $AZN

No tweets yet!

PARTNER HEADLINES

$AZN

Astrazeneca Vs. Novavax: Which Vaccine Stock Is A Better Buy?
Karen Klein 2/14/2021 4:58:18 AM

$AZN looks like the best option since it's easy to transport and so cheap to produce. But it sounds like it's not particularly effective against the new strains.

VistaGen Is Prepared For 2021 Fueled By Recent Analyst Upgrades And Large Institutional Buyers
Terrence Howard 1/11/2021 6:59:49 AM

Good article, thanks. Totally unrelated but what do you think about $AZN? I know Pfizer and Moderna have the head start on the vaccine, but it sounds like AZN's drug will be almost as effective at 90% efficacy (if they can replicate their initial test where they accidentally gave a quarter of the participants a 1/2 dose). And at $2 per vial instead of $200, I would think it will be the drug of choice for populous, yet poor nations like India, and Africa. Plus there will be no need for specialized freezers.

AstraZeneca Vaccine Only 62% Effective; Impact On Elderly Unclear As More Data Needed
Craig Newman 12/8/2020 5:20:20 PM

$AZN has not even filed or talked about filing in US or UK to my knowledge. They are hoping to get India to bite first via Serum Institute. Their trial was so F'd UP the most value to FDA is in denying to prove that other approvals are REAL..

Market Briefing For Thursday, September 10
Adam Reynolds 11/29/2020 5:39:15 PM

What's your take on the latest news on $AZN?

Good Day For Bad News
Ayelet Wolf 11/29/2020 5:37:45 PM

I thought this as well. 90% efficacy is almost as good as the 95% efficacy of the #Pfizer and #Moderna vaccines. But is a much cheaper alternative. Bullish on $AZN

Market Briefing For Thursday, September 10
Atif Ozcelik 9/10/2020 10:37:10 AM

Comments on the major vaccine producers are very useful; thank for the information on $SRNE, $AZN.

When Profits and Politics Drive Science: Rushing a Vaccine to Market for a Vanishing Virus
Adam Reynolds 6/4/2020 5:09:08 PM

Yes and Fauci and other experts said corona is likely here to stay. We will probably have seasonal outbreaks every year. There will be plenty of time to profit from a vaccine. Bullish on $AZN, $MRNA.

1 to 7 of 7 comments